Production (Stage)
Cytophage Technologies Ltd.
CYTO.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 40.80% | -68.18% | -- | -- | -- |
| Total Depreciation and Amortization | 30.20% | 35.98% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -98.95% | 223.49% | -- | -- | -- |
| Change in Net Operating Assets | 247.44% | -173.22% | -- | -- | -- |
| Cash from Operations | 17.98% | -65.15% | -- | -- | -- |
| Capital Expenditure | -502.32% | -692.60% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -104.00% | 413.39% | -- | -- | -- |
| Cash from Investing | -127.70% | 344.33% | -- | -- | -- |
| Total Debt Issued | 800.00% | 800.00% | -- | -- | -- |
| Total Debt Repaid | 21.52% | -23.51% | -- | -- | -- |
| Issuance of Common Stock | -99.85% | 151.81% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3,487.53% | -101.17% | -- | -- | -- |
| Cash from Financing | -99.82% | -102.07% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -212.79% | 170.65% | -- | -- | -- |